HR23B, a biomarker for HDAC inhibitors
<p>As our understanding of cancer biology increases and novel therapies are developed, an increasing number of predictive biomarkers are becoming clinically available. Aberrant acetylation has been strongly linked to tumourigenesis and the modulation of acetylation through targeting histone d...
Автор: | Khan, OA |
---|---|
Інші автори: | La Thangue, NB |
Формат: | Дисертація |
Мова: | English |
Опубліковано: |
2013
|
Предмети: |
Схожі ресурси
Схожі ресурси
-
Mitochondrial modulators of hypoxia-related pathways in tumours
за авторством: Snell, CE
Опубліковано: (2013) -
Role of HR23B, HDAC6 and Myd88 and their interplay in response to HDAC inhibitor treatment
за авторством: New, M
Опубліковано: (2014) -
Angiogenesis in human lung tumours
за авторством: Ferguson, ML
Опубліковано: (2008) -
Risk factors for haemorrhage in patients with haematological malignancies
за авторством: Estcourt, LJ
Опубліковано: (2014) -
Regulation of stemness and differentiation in colorectal cancer
за авторством: Gandhi, S
Опубліковано: (2010)